| URL | https://investor.lilly.com/news-releases/news-rele |
| Source | Lilly Investors |
| Date Published | 09/17/2020 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Eli Lilly and Company |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2020 |
| City reshored to: | Indianapolis |
| State(s) reshored to: | IN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals, pharmaceutical, biopharmaceutical |
| Product(s) reshored | neutralizing antibodies, LY-CoV-555 |
| What domestic positive factors made reshoring more attractive? | , Covid-19 |